Subtopic Deep Dive
Mycosis Fungoides Classification and Staging
Research Guide
What is Mycosis Fungoides Classification and Staging?
Mycosis Fungoides classification and staging uses histopathological, immunophenotypic, and molecular criteria under WHO-EORTC and ISCL/EORTC frameworks to stratify risk in cutaneous T-cell lymphoma.
The WHO-EORTC classification by Willemze (2005, Blood, 3766 citations) unified prior systems for primary cutaneous lymphomas. ISCL/EORTC revisions by Olsen et al. (2007, Blood, 1390 citations) updated staging for mycosis fungoides and Sézary syndrome incorporating tumor biology advances. The 2018 update by Willemze et al. (2019, Blood, 1301 citations) refined categories based on new evidence.
Why It Matters
Precise staging via Olsen et al. (2007) enables risk stratification, guiding therapy from skin-directed to systemic in mycosis fungoides patients. Agar et al. (2010, Journal of Clinical Oncology, 823 citations) validated revised ISCL/EORTC staging, showing improved survival predictions in cohorts. Olsen et al. (2011, Journal of Clinical Oncology, 637 citations) standardized response criteria, facilitating clinical trials and personalized treatment planning.
Key Research Challenges
Refining Prognostic Indices
Developing accurate prognostic models remains challenging due to heterogeneous disease progression in mycosis fungoides. Agar et al. (2010) validated ISCL/EORTC staging but noted limitations in early-stage predictions. Willemze et al. (2019) highlighted needs for molecular integration.
Standardizing Response Criteria
Lack of uniform endpoints hinders trial comparability in mycosis fungoides and Sézary syndrome. Olsen et al. (2011) proposed consensus criteria addressing this gap. Variability in clinical assessments persists across cohorts.
Incorporating Molecular Markers
Integrating genomic and immunophenotypic data into staging systems faces technical hurdles. Olsen et al. (2007) incorporated tumor biology but called for further refinements. Willemze (2005) noted shortcomings in prior classifications lacking molecular criteria.
Essential Papers
WHO-EORTC classification for cutaneous lymphomas
Rein Willemze · 2005 · Blood · 3.8K citations
Primary cutaneous lymphomas are currently classified by the European Organization for Research and Treatment of Cancer (EORTC) classification or the World Health Organization (WHO) classification, ...
Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)
Elise A. Olsen, Eric C. Vonderheid, Nicola Pimpinelli et al. · 2007 · Blood · 1.4K citations
Abstract The ISCL/EORTC recommends revisions to the Mycosis Fungoides Cooperative Group classification and staging system for cutaneous T-cell lymphoma (CTCL). These revisions are made to incorpora...
The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas
Rein Willemze, Lorenzo Cerroni, Werner Kempf et al. · 2019 · Blood · 1.3K citations
Abstract Primary cutaneous lymphomas are a heterogeneous group of T- and B-cell lymphomas that present in the skin with no evidence of extracutaneous disease at the time of diagnosis. The 2005 Worl...
Survival Outcomes and Prognostic Factors in Mycosis Fungoides/Sézary Syndrome: Validation of the Revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer Staging Proposal
Nita Agar, Emma Wedgeworth, Siobhan Crichton et al. · 2010 · Journal of Clinical Oncology · 823 citations
Purpose We have analyzed the outcome of mycosis fungoides (MF) and Sézary syndrome (SS) patients using the recent International Society for Cutaneous Lymphomas (ISCL)/European Organisation for Rese...
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
Elise A. Olsen, Sean Whittaker, Youn H. Kim et al. · 2011 · Journal of Clinical Oncology · 637 citations
Mycosis fungoides (MF) and Sézary syndrome (SS), the major forms of cutaneous T-cell lymphoma, have unique characteristics that distinguish them from other types of non-Hodgkin's lymphomas. Clinica...
Update on erythrodermic cutaneous T-cell lymphoma: Report of the international society for cutaneous lymphomas
Eric C. Vonderheid, Maria Grazia Bernengo, Günter Burg et al. · 2002 · Journal of the American Academy of Dermatology · 493 citations
A Randomized Trial Comparing Combination Electron-Beam Radiation and Chemotherapy with Topical Therapy in the Initial Treatment of Mycosis Fungoides
Frederic J. Kaye, Paul A. Bunn, Seth M. Steinberg et al. · 1989 · New England Journal of Medicine · 492 citations
Mycosis fungoides is a T-cell lymphoma that arises in the skin and progresses at highly variable rates. Nonradomized studies have suggested that early aggressive therapy may improve the prognosis i...
Reading Guide
Foundational Papers
Start with Willemze (2005, Blood, 3766 citations) for WHO-EORTC baseline, then Olsen et al. (2007, Blood, 1390 citations) for ISCL/EORTC staging revisions incorporating biology, followed by Agar et al. (2010) for prognostic validation.
Recent Advances
Study Willemze et al. (2019, Blood, 1301 citations) for 2018 updates refining categories; Trautinger et al. (2017) for EORTC treatment links to staging.
Core Methods
Core techniques: TNM classification (skin patches/plaques/tumors, node involvement, blood Sézary counts); response criteria (mSWAT scoring); validated in cohorts (Olsen 2007, Agar 2010).
How PapersFlow Helps You Research Mycosis Fungoides Classification and Staging
Discover & Search
PapersFlow's Research Agent uses searchPapers and citationGraph to map evolution from Willemze (2005) to Olsen et al. (2007) and Willemze et al. (2019), revealing 3766+ citations in WHO-EORTC lineage. findSimilarPapers expands to related staging proposals like Kim et al. (2007); exaSearch uncovers cohort validations such as Agar et al. (2010).
Analyze & Verify
Analysis Agent applies readPaperContent to extract TNM staging details from Olsen et al. (2007), then verifyResponse with CoVe checks claims against Willemze (2005). runPythonAnalysis processes survival data from Agar et al. (2010) cohorts using pandas for Kaplan-Meier curves; GRADE grading scores evidence strength in response criteria from Olsen et al. (2011).
Synthesize & Write
Synthesis Agent detects gaps in molecular staging post-Willemze et al. (2019) and flags contradictions between 2005 and 2018 classifications. Writing Agent uses latexEditText for staging tables, latexSyncCitations to link Olsen et al. (2007), and latexCompile for manuscripts; exportMermaid visualizes ISCL/EORTC TNM progression diagrams.
Use Cases
"Analyze survival data from Agar 2010 mycosis fungoides cohort using Python."
Research Agent → searchPapers(Agar 2010) → Analysis Agent → readPaperContent → runPythonAnalysis(pandas survival curves, matplotlib plots) → statistical verification of staging prognostic power.
"Draft LaTeX review of ISCL/EORTC staging revisions with citations."
Synthesis Agent → gap detection(Olsen 2007 vs Willemze 2019) → Writing Agent → latexEditText(staging sections) → latexSyncCitations(all provided papers) → latexCompile(PDF output with tables).
"Find code repositories analyzing mycosis fungoides staging datasets."
Research Agent → searchPapers(staging cohorts) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect(R scripts for TNM prognostic models).
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ MF staging papers) → citationGraph → DeepScan(7-step analysis with GRADE on Olsen 2007 validation). Theorizer generates hypotheses on molecular staging refinements from Willemze 2019 gaps, chaining readPaperContent → runPythonAnalysis. DeepScan verifies cohort survival claims from Agar 2010 via CoVe checkpoints.
Frequently Asked Questions
What is the definition of Mycosis Fungoides classification and staging?
It employs WHO-EORTC and ISCL/EORTC criteria including TNM for skin, nodes, viscera, and blood to stratify mycosis fungoides risk (Olsen et al., 2007; Willemze et al., 2019).
What are the primary methods in MF staging?
Methods include clinical TNM assessment, Sézary cell counts, and histopathological review; ISCL/EORTC revisions incorporate tumor/node/metastases with blood staging (Olsen et al., 2007; Agar et al., 2010).
What are the key papers on MF classification?
Willemze (2005, 3766 citations) established WHO-EORTC; Olsen et al. (2007, 1390 citations) proposed ISCL/EORTC revisions; Willemze et al. (2019, 1301 citations) updated for primary cutaneous lymphomas.
What open problems exist in MF staging?
Challenges include molecular marker integration and refined prognostics for early stages; gaps noted in Willemze (2005), Olsen (2011) response criteria, and Agar (2010) validation.
Research Cutaneous lymphoproliferative disorders research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Mycosis Fungoides Classification and Staging with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers